More weakness among IPOs as Galera, Centogene limp into marketplace

Cancer company Galera became the latest biotech whose NASDAQ IPO fell short of expectations, while shares of diagnostics company Centogene dipped after pricing its offering at the low end of its proposed range.

A third listing that was expected to price, by 89bio, did not take place. Meanwhile, listings on the Hong Kong stock exchange’s biotech chapter have resumed after a lull, with cancer company Tot Biopharm poised to begin trading Friday after pricing its IPO. ...